ÂÜÀòÂÒÂ×

Dr. Cravatt is a Professor in the Department of Chemistry and Gilula Chair Chemical Biology at The Scripps Research Institute.

His research group is interested in understanding the roles that enzymes play in physiological and pathological processes, especially as pertains to the nervous system and cancer. To address this challenge, they develop and apply an array of genetic, pharmacological, and proteomic/metabolomic technologies. The Cravatt group has obtained fundamental insights into the chemical, biochemical, and physiological workings of several important mammalian serine hydrolases, including enzymes involved in the neurobiology of pain and cancer metabolism and malignancy.

Dr. Cravatt obtained his undergraduate education at Stanford University, receiving a B.S. in the Biological Sciences and a B.A. in History. He then trained with Drs. Dale Boger and Richard Lerner and received a Ph.D. in Macromolecular and Cellular Structure and Chemistry from The Scripps Research Institute (TSRI) in 1996. Professor Cravatt joined the faculty at TSRI in 1997 as a member of the Skaggs Institute for Chemical Biology in the departments of Cell Biology and Chemistry. Dr. Cravatt is a co-founder and scientific advisor of Activx Biosciences, Abide Therapeutics and Vividion Therapeutics. His honors include a Searle Scholar Award (1998-2001), the Eli Lilly Award in Biological Chemistry (2004), a Cope Scholar Award (2005), the Irving Sigal Young Investigator Award (2007), the Tetrahedron Young Investigator Award in Bioorganic and Medicinal Chemistry (2008), a MERIT award from the National Cancer Institute (2009), Robert M. Scarborough Award (2017), Jeremy Knowles Award (2019), AACR Award for Outstanding Achievement in Chemisty in Cancer Research and inducted member of the National Academy of Sciences (2014) as well as being elected as a member of the National Academy of Inventors (2015), American Academy of Arts and Sciences (2016), and the National Academy of Medicine (2017).